Related Experiment Video

Updated: Jan 5, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.2K

Proanthocyanidins attenuate breast cancer-induced bone metastasis by inhibiting Irf-3/c-jun activation

Shuangfei Guo1, Wei Zhu, Ziqing Yin

  • 1Department of Orthopaedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.

Anti-Cancer Drugs
|October 19, 2019
PubMed

Insights

Proanthocyanidins (PACs) protect bone by targeting Irf-3 to reduce osteoclast activation and induce apoptosis in breast cancer bone metastasis. This offers a novel therapeutic approach for abnormal bone metabolism.

Area of Science:

  • Oncology
  • Bone Biology
  • Pharmacology

Background:

  • Jnk-mediated Irf-3/c-Jun signaling is crucial in regulating osteoclastogenesis.
  • Breast cancer metastasis to bone involves abnormal osteoclast activation.
  • Nuclear factor kappa-B ligand (RANKL) plays a key role in osteoclast differentiation.

Purpose of the Study:

  • To investigate the effect of proanthocyanidins (PACs) on breast cancer-induced osteoclast activation.
  • To elucidate the molecular mechanisms by which PACs exert bone-protective effects.
  • To evaluate the therapeutic potential of PACs in a bone metastasis model.

Main Methods:

  • In vitro studies on osteoclast precursors.
  • Analysis of apoptosis-related proteins (bax/bcl-2 ratio) and caspase-3 activity.
  • In vivo assessment using a bone metastasis model of breast cancer.

Main Results:

  • Proanthocyanidins (PACs) target Irf-3, alleviating RANKL-induced osteoclastogenesis.
  • PACs induce apoptosis of osteoclast precursors by modulating bax/bcl-2 ratio and activating caspase-3.
  • PACs demonstrated bone-protective effects in a preclinical model of breast cancer bone metastasis.

Conclusions:

  • PACs offer a novel therapeutic strategy by targeting Irf-3 to inhibit osteoclast activation.
  • PACs mitigate breast cancer-induced bone abnormalities through apoptosis induction.
  • These findings highlight PACs as a potential intervention for managing bone metastasis in breast cancer.

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.6K
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.5K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
7.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
10.3K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
8.2K